Major Milestones Ahead Should Drive Plandai Shares Higher

Marketwired

BALTIMORE, MD--(Marketwired - Aug 1, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a research update that a series of upcoming events for the balance of 2013 serve as major milestones that should drive the shares of Plandai Biotechnology Inc.'s (OTCQB: PLPL) to higher levels.

According to the research update released by Goldman Small Cap Research today, investors will notice that a significant amount of research and development activity is slated to commence in the fourth quarter of 2013.

Two important studies slated to start at the end of the year include the first study to test the absorption properties of the green-tea based Catechin Complex in human subjects. The objective of this investigation is to measure human bioavailability of Phytofare™ Catechin Complex. This study will be followed by a trial to test the effects of Phytofare™ Catechin Complex in inducing weight loss while also improving cholesterol and lowering blood pressure. Separately, independent scientific investigations of Phytofare™ Catechin Complex in both powder and nano-encapsulated forms will be undertaken in 4Q13 both in vivo and mouse models to validate the extract for oral and topical formulations as an antimalarial drug.

In addition, meaningful production and distribution should commence in 4Q13 as well.  Plandai expects commercial production to commence by the end of Q4 with a daily volume estimated at 290 kg of total formulated Phytofare™ catechin complex. The Company's nano-encapsulated product will be made available sometime in 1Q14. Also planned for Q4 is the distribution and marketing of Phytofare™ as noted in a previous Company press release.

Plandai partner Nutricare PLC oversees all aspects of marketing Phytofare™ extracts for nutriceutical applications and Phyto Nutricare will pay the Company a one-time license fee of $2M and a recurring payment equal to 5% of future profits from Phytofare™ product sales. Clearly, with significant development and operational milestones around the corner, Plandai's shares should enjoy meaningful activity ahead of these events.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments (0)